Myasthenia Gravis
Condition Description
A weakness and rapid fatigue of muscles under voluntary control.
The condition is caused by a breakdown in communication between nerves and muscles.
Symptoms include weakness in the arm and leg muscles, double vision, and difficulties with speech and chewing.
Active Trials
Upcoming Trials
Past Trials
-
TRIAL TITLE: A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
DESCRIPTION: The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
SPONSOR: Immunovant Sciences GmbH
INDICATION: Myasthenia Gravis
STUDY PROTOCOL: RVT-1401-2002
PHASE: 2a
STATUS: Completed
RECRUITING PATIENTS: No